A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer

Clinical Cancer Research

Volumn 5, Issue 9, 1999, Pages 2324-2329

  Bauer, Kenneth S ^a   Figg, William D ^a,b   Hamilton, J Michael ^a   Jones, Elizabeth C ^a   Premkumar, Ahalya ^a   Steinberg, Seth M ^a   Dyer, Valerie ^a   Linehan, W Marsten ^b   Pluda, James M ^a   Reed, Eddie ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; PROSTATE SPECIFIC ANTIGEN; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER;

ADENOCARCINOMA; AGED; ANDROGENS; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; TRIAZOLES;

EID: 0032884773     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Kohn, E. C., and Liotta, L. A. L651582: a novel antiproliferative and antimetastases agent. J. Natl. Cancer Inst., 82: 54-60, 1990.
2. Felder, C. C., Ma, A. L., Liotta, L. A., et al. The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release. J. Pharmacol. Exp. Ther., 2.57: 967-971, 1991.
3. Kohn, E. C., Sandeen, M. A., and Liotta, L. A. In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates. Cancer Res., 52: 3208-3212, 1992.
4. Wasilenko, W. J., Palad, A. J., Somers, K. D., et al. Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines. Int. J. Cancer, 68: 259-264, 1996.
5. Lambert, P. A., Somers, K. D., Kohn, E. C., et al. Antiproliferative and antiinvasive effects of carboxyamido-triazole on breast cancer cell lines. Surgery (St. Louis), 122: 372-372, 1997.
6. Jacobs, W., Mikkelsen, T., Smith, R., et al. Inhibitory effects of CAI in glioblastoma growth and invasion. J. Neuro-Oncol., 32: 93-101. 1997.
7. Kohn, E. C., Reed, E., Sarosy, G. A., et al. Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res., 56: 569-573, 1996.
8. Berlin, J., Tutsch, K. D., Hutson, P., et al. Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor. J. Clin. Oncol., 15: 781-789, 1997.
9. Kohn, E. C., Figg, W. D., Sarosy, G. A., et al. Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations. J. Clin. Oncol., 15: 1985-1993, 1997.
10. Simmons, B. R., Bauer, K. S., McCall, N. A., et al. An optimized method for the quantitation of carboxyamido-triazole (CAI) in human plasma with solid phase extraction and reversed phase HPLC. Anal. Lett., 39: 2009-2021, 1997.
11. D'Argenia, D. Z., and Schumitzky, A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput. Prog. Biomed., 9: 115-134, 1979.
12. Kohn, E. C., Alessandro, R., Spoonster, J., et al. Angiogenesis: role of calcium-mediated signal transduction. Proc. Natl. Acad. Sci. USA, 92: 1307-1311, 1995.
13. Figg, W. D., Cole, K. A., Reed, E., et al. Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction. Clin. Cancer Res., 1: 797-803, 1995.